Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03342664 · ClinicalTrials.gov registry record · NA
MIND: Artemis in the Removal of Intracerebral Hemorrhage
A NA study, sponsored by Penumbra.
- Completed
- Registry status
- NA
- Development phase
- 236
- Enrollment target
NCT03342664: Completed NA study, sponsored by Penumbra.
NCT03342664 is a NA study that has completed, run by Penumbra. The registered enrollment target is 236 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03342664, a NA study, has completed, sponsored by Penumbra.
- COMPLETED
- Registry status
- NA
- Development phase
- 236 participants
- Enrollment target
Study Summary
The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).
Primary Outcome
Modified Rankin scale measures degree of disability or functional impairment on a scale of 0 (no symptoms) to 5 (severe disability), 6 (expired), where higher scores mean a worse outcome
Interventions
- DEVICE Artemis + Medical Management
- OTHER Best Medical Management Alone (MM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2024-09-23 |
| Phase | NA |
What the finished NCT03342664 record still lists
NCT03342664 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Artemis + Medical Management is the first listed.
NCT03342664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03342664 about?
NCT03342664 is a clinical study titled "MIND: Artemis in the Removal of Intracerebral Hemorrhage". The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).
What is the current status of trial NCT03342664?
This trial is currently completed. It is a NA study. The enrollment target is 236 participants. The study started on 2018-02-06. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT03342664?
The interventions under investigation include: Artemis + Medical Management (DEVICE), Best Medical Management Alone (MM) (OTHER).
Who is sponsoring clinical trial NCT03342664?
This trial is sponsored by Penumbra, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03342664's enrollment target sits among peer trials
236 461st of 2000 higher than 1,540 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI